Susquehanna International Group, LLP Genmab A/S Transaction History
Susquehanna International Group, LLP
- $688 Billion
- Q2 2025
A detailed history of Susquehanna International Group, LLP transactions in Genmab A/S stock. As of the latest transaction made, Susquehanna International Group, LLP holds 30,394 shares of GMAB stock, worth $995,403. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,394
Previous 12,700
139.32%
Holding current value
$995,403
Previous $248,000
152.82%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding GMAB
# of Institutions
242Shares Held
65.2MCall Options Held
32.5KPut Options Held
55K-
Alliancebernstein L.P. New York, NY10.7MShares$349 Million0.08% of portfolio
-
Orbis Allan Gray LTD Hamilton, D07.92MShares$259 Million1.07% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$166 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.57MShares$117 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.45MShares$113 Million0.05% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $21.6B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...